Literature DB >> 28634672

HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT).

İsa Burak Güney1.   

Abstract

Year:  2017        PMID： 28634672     DOI： 10.1007/s12029-017-9973-2

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  16 in total

Review 1.  Positron emission tomography imaging in oncology.

Authors:  D Delbeke; W H Martin
Journal:  Radiol Clin North Am       Date:  2001-09       Impact factor: 2.303

Review 2.  General selection criteria of patients for radioembolization of liver tumors: an international working group report.

Authors:  Douglas Coldwell; Bruno Sangro; Harpreet Wasan; Riad Salem; Andrew Kennedy
Journal:  Am J Clin Oncol       Date:  2011-06       Impact factor: 2.339

3.  (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma.

Authors:  Arun Sasikumar; Ajith Joy; Raviteja Nanabala; M R A Pillai; Boben Thomas; K R Vikraman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-08       Impact factor: 9.236

4.  Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation.

Authors:  Laura M Kulik; Bassel Atassi; Lodewijk van Holsbeeck; Tameem Souman; Robert J Lewandowski; Mary F Mulcahy; Russell D Hunter; Albert A Nemcek; Michael M Abecassis; Kenneth G Haines; Riad Salem
Journal:  J Surg Oncol       Date:  2006-12-01       Impact factor: 3.454

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver.

Authors:  David S K Lu; Nam C Yu; Steven S Raman; Piyaporn Limanond; Charles Lassman; Kathryn Murray; Myron J Tong; Rafael G Amado; Ronald W Busuttil
Journal:  Radiology       Date:  2005-01-28       Impact factor: 11.105

Review 7.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

8.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

9.  Liver disease induced by radioembolization of liver tumors: description and possible risk factors.

Authors:  Bruno Sangro; Belen Gil-Alzugaray; Javier Rodriguez; Iosu Sola; Antonio Martinez-Cuesta; Antonio Viudez; Ana Chopitea; Mercedes Iñarrairaegui; Javier Arbizu; Jose I Bilbao
Journal:  Cancer       Date:  2008-04-01       Impact factor: 6.860

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079
View more
  1 in total

1.  Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma.

Authors:  Nguyen Van Thai; Nguyen Tien Thinh; Thai Doan Ky; Mai Hong Bang; Dinh Truong Giang; Le Ngoc Ha; Mai Hong Son; Dao Duc Tien; Hyun Woong Lee
Journal:  BMC Gastroenterol       Date:  2021-05-12       Impact factor: 3.067
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.